Showing results (221-230 of 226) with videos related to
Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 226 results.
Cancer Cell|July 29, 2026
Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapyAnne-Laure Mallard de La Varende, Ai-Ling Tian, Simon Thomas, et al.Minerva Urology and Nephrology|August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinationsCamillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.European Urology Oncology|July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.Journal of Personalized Medicine|May 28, 2022
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 StudyMatteo Brunelli, Guido Martignoni, Giorgio Malpeli, et al.Cancer Immunology, Immunotherapy : CII|April 18, 2024
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 studyFrancesco Massari, Matteo Santoni, Hideki Takeshita, et al.Cancer Immunology, Immunotherapy : CII|September 7, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective studyOndřej Fiala, Sebastiano Buti, Hideki Takeshita, et al.Pageof 23